menù
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Bianchi Giulia Valeria
Main Facility: Medical Oncology 1
Drug: Arm A: MK-2870 Arm B: MK-2870+Pembrolizumab Arm C: Paclitaxel/ Nab-Paclitaxel/ Capecitabine/ Liposomal Doxorubicin
Principal Investigator: Dott. Maccauro Marco
Main Facility: Nuclear Medicine
Drug: Iodine-124 (for PET imaging and dosimetry) Iodine-131 (for targeted)
Principal Investigator: Dr. Procopio Giuseppe
Main Facility: Genitourinary Medical Oncology
Drug: Pembrolizumab + Enfortumab
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Breast Medical Oncology
Drug: RO7771950
Drug: RO7771950 (ZN-A-1041)
Principal Investigator: Dott. Alfieri Salvatore
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: Avelumab, Cetuximab
Principal Investigator: Dr. Prelaj Arsela
Main Facility: Thoracic Oncology Unit
Drug: MK2870 (sacituzumab tirumotecan) Docetaxel Pemetrexed
Principal Investigator: Dr. Lo Russo Giuseppe
Drug: MK-2870 (sacituzumab tirumotecan) Pembrolizumab
Principal Investigator: Dr. Gronchi Alessandro
Main Facility: General Surgery 7 – Sarcomas
Drug: For high-risk Dedifferentiated Liposarcoma (DDLPS): Doxorubicin + Ifosfamide. For Leiomyosarcoma (LMS): Doxorubicin + Dacarbazine.
Principal Investigator: Dott.ssa Verzoni Elena
Drug: Saruparib (AZD5305)
Principal Investigator: Dott.ssa Guidetti Anna
Main Facility: Haematology
Drug: Ruxolitinib
Principal Investigator: Associate Professor Licitra Lisa Francesca Linda
Drug: MEDI5752
Drug: Giredestrant + inibitore di CDK4/6 Fulvestrant + inibitore di CDK4/6
Drug: Arm A: inavolisib + letrozolo + palbociclib o ribociclib Arm B: placebo + letrozolo + palbociclib o ribociclib
Drug: RO7198574 + Inavolisib RO7198574 + Placebo
Principal Investigator: Dr. Beninato Teresa
Drug: BNT327
Principal Investigator: Prof. Corradini Paolo
Drug: KTE-X-19 (brexucabtagene autoleucel)
Drug: MK-2870
Principal Investigator: Dott.ssa Ducceschi Monika
Main Facility: Gynecologic Surgical Oncology
Drug: MK-2870, also known as Sacituzumab tirumotecan
Drug: BMS-986393 (Arlocabtagene Autoleucel)
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe